Canada
· Delayed Price · Currency is CAD NurExone Biologic Statistics
Total Valuation
TSXV:NRX has a market cap or net worth of CAD 53.05 million. The enterprise value is 52.24 million.
| Market Cap | 53.05M |
| Enterprise Value | 52.24M |
Important Dates
The last earnings date was Tuesday, May 27, 2025.
| Earnings Date | May 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TSXV:NRX has 78.01 million shares outstanding. The number of shares has increased by 44.76% in one year.
| Current Share Class | 78.01M |
| Shares Outstanding | 78.01M |
| Shares Change (YoY) | +44.76% |
| Shares Change (QoQ) | +3.55% |
| Owned by Insiders (%) | 6.05% |
| Owned by Institutions (%) | n/a |
| Float | 73.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 28.04 |
| P/TBV Ratio | 28.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.27 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -7.50 |
Financial Position
The company has a current ratio of 2.47, with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.47 |
| Quick Ratio | 1.31 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | -304.68 |
Financial Efficiency
Return on equity (ROE) is -234.45% and return on invested capital (ROIC) is -144.67%.
| Return on Equity (ROE) | -234.45% |
| Return on Assets (ROA) | -115.19% |
| Return on Invested Capital (ROIC) | -144.67% |
| Return on Capital Employed (ROCE) | -364.78% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +28.30% in the last 52 weeks. The beta is 0.02, so TSXV:NRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.02 |
| 52-Week Price Change | +28.30% |
| 50-Day Moving Average | 0.68 |
| 200-Day Moving Average | 0.64 |
| Relative Strength Index (RSI) | 52.12 |
| Average Volume (20 Days) | 19,796 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.32M |
| Pretax Income | -8.34M |
| Net Income | -8.34M |
| EBITDA | -8.20M |
| EBIT | -8.32M |
| Earnings Per Share (EPS) | -0.12 |
Balance Sheet
The company has 845,162 in cash and 44,558 in debt, giving a net cash position of 800,604 or 0.01 per share.
| Cash & Cash Equivalents | 845,162 |
| Total Debt | 44,558 |
| Net Cash | 800,604 |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 1.89M |
| Book Value Per Share | 0.03 |
| Working Capital | 1.17M |
Cash Flow
In the last 12 months, operating cash flow was -6.34 million and capital expenditures -632,434, giving a free cash flow of -6.97 million.
| Operating Cash Flow | -6.34M |
| Capital Expenditures | -632,434 |
| Free Cash Flow | -6.97M |
| FCF Per Share | -0.09 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TSXV:NRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -44.76% |
| Shareholder Yield | n/a |
| Earnings Yield | -15.71% |
| FCF Yield | -13.14% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |